Navigating Diagnostic Ambiguity and Histologic Uncertainty in HCCByTargeted Oncology StaffMarch 13th 2026
FDA Fast Track Highlights Potential of Metabolic Reprogramming in HCCByAndrea Eleazar, MHSFebruary 20th 2026
Nivolumab/Ipilimumab in HCC Offers Clinical Gains but Carries Economic BurdenByAndrea Eleazar, MHSFebruary 13th 2026
Irpagratinib Gains FDA Fast Track Status in FGF19-Overexpressing Advanced HCCByAndrea Eleazar, MHSFebruary 11th 2026
FDA Review Restarts for Rivoceranib/Camrelizumab in Advanced HCCByAndrea Eleazar, MHSFebruary 3rd 2026